Tennessee Oncology - Chattanooga

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Colorectal cancer2 trials
• Prostate cancer2 trials
• Triple-negative breast cancer2 trials
• Endometrial cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial

Phase

• Phase 38 trials
• Phase 24 trials
• Phase 1/22 trials
• Phase 2/31 trial

Status

• Completed7 trials
• Recruiting5 trials
• Terminated2 trials
• Active, not recruiting1 trial

Lead sponsor

• Janssen Research & Development, LLC4 trials
• Eli Lilly and Company2 trials
• Hoffmann-La Roche2 trials
• Arcus Biosciences, Inc.1 trial
• G1 Therapeutics, Inc.1 trial
• and 5 more

Running trials

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Wade Iams (principal investigator)

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

  Contact: Wade Iams (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Colorectal cancer1 recruiting
• Melanoma1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

  NCT04984811· Phase 2· NeoImmuneTech· Source

• Terminated

  A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

  NCT04577963· Phase 1/2· Hutchmed· Source

• Completed

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· Phase 3· G1 Therapeutics, Inc.· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

  NCT04619797· Phase 2/3· Hoffmann-La Roche· Source

• Completed

  A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT04513925· Phase 3· Hoffmann-La Roche· Source

• Completed

  Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

  NCT04381832· Phase 1/2· Arcus Biosciences, Inc.· Source

• Completed

  Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT03781063· Phase 2· Sermonix Pharmaceuticals Inc.· Source

• Completed

  Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

  NCT03977467· Phase 2· SCRI Development Innovations, LLC· Source

• Completed

  A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

  NCT03901963· Phase 3· Janssen Research & Development, LLC· Source